dorsaVi Launches Artemis Labs with Next-Gen RRAM to Power AI and Robotics

A Bold Step into Robotics and AI

dorsaVi Ltd (ASX, DVL), known for its FDA-cleared wearable movement sensors, has taken a significant leap by launching Artemis Labs, a wholly owned subsidiary dedicated to pushing the boundaries of human movement technology into robotics and digital systems. This move signals dorsaVi’s ambition to evolve from a clinical sensor provider into a key player in next-generation AI and robotics innovation.

Artemis Labs will serve as a cross-disciplinary innovation hub, bringing together expertise in AI, embedded systems, additive manufacturing, and human-machine interfaces. Central to its mission is the creation of a proprietary repository of human movement data, captured through dorsaVi’s existing sensor platforms. This dataset will train edge-deployable AI models designed to predict, classify, and replicate biomechanical motion in real time.

Leveraging Cutting-Edge RRAM Technology

A key technological pillar for Artemis Labs is the integration of resistive random-access memory (RRAM) technology, licensed exclusively from Nanyang Technological University in Singapore. RRAM offers ultra-low power consumption and rapid responsiveness, ideal for on-device AI processing. This positions dorsaVi at the forefront of neuromorphic computing, enabling reflexive, real-time decision-making in robotics and healthcare devices.

The applications envisioned are diverse and ambitious, from zero-code robotic training; where robots learn tasks by mimicking human movement without programming; to camera-less spatial tracking based solely on limb kinematics. Adaptive medical interfaces that adjust assistance based on muscle or cardiac activity patterns also highlight the potential to enhance patient care dynamically.

Strategic Vision and Market Implications

Chairman Gernot Abl emphasized that Artemis Labs represents more than a natural progression; it is a strategic leap into emerging high-growth sectors. By consolidating research and commercialisation efforts, dorsaVi aims to unlock new revenue streams beyond its established clinical markets, particularly in the United States. The initiative also promises to differentiate and strengthen dorsaVi’s core clinical offerings through advanced AI capabilities.

The company plans a staged rollout focusing on AI model development, technology integration, expansion into complementary edge computing technologies, and commercial partnerships. Early engagement with robotics, digital health, and industrial automation partners suggests a proactive approach to market entry and collaboration.

While the announcement does not provide detailed financial forecasts or timelines, the strategic direction is clear, dorsaVi is positioning itself at the intersection of wearable sensor data, AI, and robotics, leveraging proprietary technology to create intelligent systems that extend human movement into machines.